PRELUDE THERAPEUTICS INC Weighted Average Number of Shares Outstanding, Basic and Diluted
PRELUDE THERAPEUTICS INC (PRLD) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 47.07 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-10
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 47.07M shares, a 4.31% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 46.68M shares, a 9.12% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 46.33M shares, a 1350.34% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 46.06M shares, a 2120.57% increase year-over-year.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 46.05M shares, a 269.03% increase from fiscal 2020.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 12.48M shares, a 647.86% increase from fiscal 2019.
- PRELUDE THERAPEUTICS INC weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 1.67M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 47.07M shares 10-Q · filed 2022-05-10 | 46.87M shares derived: average of 2 quarters · filed 2022-05-10 | 46.69M shares derived: average of 3 quarters · filed 2022-05-10 | 46.53M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 46.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 46.50M shares derived: average of 2 quarters · filed 2022-03-17 | 46.35M shares derived: average of 3 quarters · filed 2022-03-17 | 46.05M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 46.33M shares 10-Q · filed 2021-11-12 | 46.19M shares derived: average of 2 quarters · filed 2021-11-12 | 45.84M shares 10-Q · filed 2021-11-12 | 45.07M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2021-06-30 | 46.06M shares 10-Q · filed 2021-08-12 | 45.59M shares 10-Q · filed 2021-08-12 | 44.65M shares derived: average of 3 quarters · filed 2022-05-10 | 34.29M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2021-03-31 | 45.12M shares 10-Q · filed 2022-05-10 | 43.95M shares derived: average of 2 quarters · filed 2022-05-10 | 30.36M shares derived: average of 3 quarters · filed 2022-05-10 | 23.29M shares derived: average of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | 42.77M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 22.98M shares derived: average of 2 quarters · filed 2022-03-17 | 16.01M shares derived: average of 3 quarters · filed 2022-03-17 | 12.48M shares 10-K · filed 2022-03-17 |
| 2020-09-30 | 3.19M shares 10-Q · filed 2021-11-12 | 2.63M shares derived: average of 2 quarters · filed 2021-11-12 | 2.38M shares 10-Q · filed 2021-11-12 | 2.23M shares derived: average of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | 2.07M shares 10-Q · filed 2021-08-12 | 1.96M shares 10-Q · filed 2021-08-12 | 1.91M shares derived: average of 3 quarters · filed 2021-08-12 | 1.86M shares derived: average of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | 1.86M shares 10-Q · filed 2021-05-11 | 1.83M shares derived: average of 2 quarters · filed 2021-05-11 | 1.79M shares derived: average of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | 1.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | 1.76M shares derived: average of 2 quarters · filed 2021-03-16 | 1.67M shares 10-K · filed 2021-03-16 | |
| 2019-09-30 | 1.71M shares 10-Q · filed 2020-11-10 | 1.62M shares 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |